Economic analyses of genetic tests in personalized medicine: clinical utility first, then cost utility.
作者信息
Grosse Scott D
机构信息
Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
出版信息
Genet Med. 2014 Mar;16(3):225-7. doi: 10.1038/gim.2013.158. Epub 2013 Oct 10.
Abstract
摘要
相似文献
1
Economic analyses of genetic tests in personalized medicine: clinical utility first, then cost utility.
Genet Med. 2014 Mar;16(3):225-7. doi: 10.1038/gim.2013.158. Epub 2013 Oct 10.
2
The economic value of personalized medicine tests: what we know and what we need to know.
Genet Med. 2014 Mar;16(3):251-7. doi: 10.1038/gim.2013.122. Epub 2013 Oct 17.
3
Personalized Medicine in the Resource-poor World.
R I Med J (2013). 2016 Nov 1;99(11):8-9.
4
Payer Preferences and Willingness to Pay for Genomic Precision Medicine: A Discrete Choice Experiment.
J Manag Care Spec Pharm. 2020 Apr;26(4):529-537. doi: 10.18553/jmcp.2020.26.4.529.
5
Is personalized medicine a panacea for health management? Some thoughts on its desirability.
Eur J Health Econ. 2015 Jun;16(5):455-7. doi: 10.1007/s10198-014-0665-6.
6
Genetic testing in combination with preventive donepezil treatment for patients with amnestic mild cognitive impairment: an exploratory economic evaluation of personalized medicine.
Mol Diagn Ther. 2012 Dec;16(6):389-99. doi: 10.1007/s40291-012-0010-7.
7
Personalizing antiplatelet therapy-moving to clinics.
Eur J Clin Pharmacol. 2013 May;69(5):1191. doi: 10.1007/s00228-012-1445-9. Epub 2012 Nov 13.
8
US personalized-medicine industry takes hit from Supreme Court.
Nature. 2016 Aug 25;536(7617):382. doi: 10.1038/nature.2016.20436.
9
In response: Genomic profile of breast cancer.
Expert Rev Pharmacoecon Outcomes Res. 2015 Jun;15(3):395-7. doi: 10.1586/14737167.2015.1025760. Epub 2015 Mar 22.
10
Personalized Medicine: How Studying Individual Differences Can Shed Light on Treating Thousands of Patients: An Interview with Richard Lifton, PhD.
Yale J Biol Med. 2015 Nov 24;88(4):407-11. eCollection 2015 Dec.
引用本文的文献
1
Application of Genomic Selection in Beef Cattle Disease Prevention.
Animals (Basel). 2025 Jan 20;15(2):277. doi: 10.3390/ani15020277.
2
Pharmacogenomic testing in paediatrics: Clinical implementation strategies.
Br J Clin Pharmacol. 2022 Oct;88(10):4297-4310. doi: 10.1111/bcp.15181. Epub 2022 Feb 7.
3
A proposed approach to accelerate evidence generation for genomic-based technologies in the context of a learning health system.
Genet Med. 2018 Apr;20(4):390-396. doi: 10.1038/gim.2017.122. Epub 2017 Aug 10.
4
The Impact of Whole-Genome Sequencing on the Primary Care and Outcomes of Healthy Adult Patients: A Pilot Randomized Trial.
Ann Intern Med. 2017 Jun 27;167(3):159-169. doi: 10.7326/M17-0188. Print 2017 Aug 1.
5
Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations.
Genet Med. 2016 Dec;18(12):1171-1180. doi: 10.1038/gim.2016.29. Epub 2016 Apr 14.
6
Epidemiology matters: peering inside the "black box" in economic evaluations of genetic testing.
Genet Med. 2016 Oct;18(10):963-5. doi: 10.1038/gim.2016.121. Epub 2016 Sep 8.
7
The Use of Economic Evaluation to Inform Newborn Screening Policy Decisions: The Washington State Experience.
Milbank Q. 2016 Jun;94(2):366-91. doi: 10.1111/1468-0009.12196.
8
Assessing the Costs and Cost-Effectiveness of Genomic Sequencing.
J Pers Med. 2015 Dec 10;5(4):470-86. doi: 10.3390/jpm5040470.
9
When is Genomic Testing Cost-Effective? Testing for Lynch Syndrome in Patients with Newly-Diagnosed Colorectal Cancer and Their Relatives.
Healthcare (Basel). 2015;3(4):860-78. doi: 10.3390/healthcare3040860. Epub 2015 Sep 24.
10
'Someday it will be the norm': physician perspectives on the utility of genome sequencing for patient care in the MedSeq Project.
Per Med. 2015;12(1):23-32. doi: 10.2217/pme.14.68.
本文引用的文献
1
The economic value of personalized medicine tests: what we know and what we need to know.
Genet Med. 2014 Mar;16(3):251-7. doi: 10.1038/gim.2013.122. Epub 2013 Oct 17.
2
Value-of-information analysis within a stakeholder-driven research prioritization process in a US setting: an application in cancer genomics.
Med Decis Making. 2013 May;33(4):463-71. doi: 10.1177/0272989X13484388.
3
Modeling uncertain outcomes of genetic testing: factor V Leiden mutation and pregnant women.
Genet Med. 2013 May;15(5):335-7. doi: 10.1038/gim.2013.17. Epub 2013 Feb 28.
4
A risk-benefit analysis of factor V Leiden testing to improve pregnancy outcomes: a case study of the capabilities of decision modeling in genomics.
Genet Med. 2013 May;15(5):374-81. doi: 10.1038/gim.2012.139. Epub 2012 Nov 8.
5
Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis.
Ann Intern Med. 2011 Jul 19;155(2):69-79. doi: 10.7326/0003-4819-155-2-201107190-00002.
6
Does adjusting for health-related quality of life matter in economic evaluations of cancer-related interventions?
Expert Rev Pharmacoecon Outcomes Res. 2011 Feb;11(1):113-9. doi: 10.1586/erp.11.1.
7
Pharmacoeconomic evaluation of warfarin pharmacogenomics.
Expert Opin Pharmacother. 2011 Feb;12(3):435-41. doi: 10.1517/14656566.2011.521153. Epub 2011 Jan 14.
8
Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members.
Genet Med. 2011 Jan;13(1):67-76. doi: 10.1097/GIM.0b013e3181fbe46f.
9
Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population.
Cancer Prev Res (Phila). 2011 Jan;4(1):9-22. doi: 10.1158/1940-6207.CAPR-10-0262. Epub 2010 Nov 18.
10
A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice.
Genet Med. 2010 Nov;12(11):686-93. doi: 10.1097/GIM.0b013e3181eff533.
Zotero 插件